-transparent.png){kind=logo}
Diffuse oesophageal spasm is a functional oesophageal motility disorder of unknown aetiology, which appears to be due to a disturbance of the normal pharmacological timing of propulsive contraction occurring in the oesophageal body after swallowing. The lack of pathophysiological understanding may be due to the fact that there is more than one pathophysiological pathway causing symptoms of diffuse oesophageal spasm. Barium studies, oesophageal scintigraphy and fiberoptic examination can be helpful in finding the correct diagnosis, but manometry is still the gold standard of diagnostic procedures. Similar to other spastic oesophageal motility disorders, pharmacological treatment of diffuse oesophageal spasm includes nitrates, calcium antagonists, anticholinergics and antidepressants with varying beneficial effects. Botulinum toxin, which provides sufficient treatment as measured by symptom score and manometric patterns in patients with achalasia, was recently evaluated for the treatment of diffuse oesophageal spasm in small patient selections with promising results.
M Storr, and
H D Allescher, and
M Classen
January 2007,
Revista de gastroenterologia de Mexico,
M Storr, and
H D Allescher, and
M Classen
August 2007,
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,
M Storr, and
H D Allescher, and
M Classen
November 2002,
The Urologic clinics of North America,
M Storr, and
H D Allescher, and
M Classen
May 2011,
Drug and therapeutics bulletin,
M Storr, and
H D Allescher, and
M Classen
December 1982,
Lancet (London, England),
M Storr, and
H D Allescher, and
M Classen
January 2008,
International journal of speech-language pathology,
M Storr, and
H D Allescher, and
M Classen
January 1987,
Lancet (London, England),
M Storr, and
H D Allescher, and
M Classen
August 1997,
Gut,
M Storr, and
H D Allescher, and
M Classen
March 1981,
Gut,
